A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache


About this study

This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosed with episodic migraine at least 6 months before study
  • At least 3 consecutive months of stable migraine headaches before study
  • At least 4-14 headache days per month, of which 4-14 may be migraines
  • Must not have failed on more than 2 classes of migraine preventatives

Exclusion Criteria:

  • Previous use of the experimental device
  • Pregnant
  • Using more than 1 concurrent migraine preventive
  • History of cardiovascular disease
  • Work night shifts
  • Diagnosed with vestibular migraine
  • Menstrual migraines exclusively
  • Diagnosed with post-traumatic migraine
  • Have a history of unstable mood or anxiety disorder
  • Use a hearing aid
  • Have a cochlear implant
  • Have chronic tinnitus
  • Have temporomandibular joint disease
  • Diagnosed with traumatic brain injury
  • Diagnosed with neurological disease other than headaches
  • Diagnosed vestibular and/or balance dysfunction
  • History of abusing alcohol or other drugs
  • Are experiencing medication overuse headaches
  • Have had eye surgery in the previous 3 months
  • Have had ear surgery in the previous 6 months
  • Have active ear infections or a perforated tympanic membrane
  • Have participated in another clinical trial in the last 30 days
  • Are currently participating in another clinical trial
  • Using Botulinum toxin-based treatments for migraines or cosmetic reasons
  • Taking anti-emetics more than 2 times per week (consistently)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Rashmi Halker Singh, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer